Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the approval of ramucirumab plus paclitaxel for gastric cancer.
Venook says the approval is a benefit for all oncologists. While ramucirumab was already being combined with other agents, oncologists now know its benefit when combined with paclitaxel.
Ramucirumab’s expanded approval was based on two studies- one evaluating the drug as monotherapy and one evaluating the drug in combination with a taxane, Venook says.
Venook also says that ramucirumab is being evaluated in other disease.
<<< View more from the 2014 Chemotherapy Foundation Symposium